<DOC>
	<DOCNO>NCT02013310</DOCNO>
	<brief_summary>This Phase 2 randomize , multicenter , double-blind , placebo-controlled , parallel-group study evaluate efficacy HT-0712 improve memory cognitive performance subject Age-Associated Memory Impairment ( AAMI )</brief_summary>
	<brief_title>HT-0712 v . Placebo Subjects With Age-Associated Memory Impairment ( AAMI )</brief_title>
	<detailed_description />
	<mesh_term>Memory Disorders</mesh_term>
	<criteria>Main Complaints memory loss everyday life Performance least one standard deviation mean establish young adult standardized memory test Absence dementia Intact global intellectual function Main Diagnosis Mild Cognitive Impairment ( MCI ) Alzheimer 's Disease Evidence dementia Evidence psychiatric neurological disorder could influence cognition contribute subject 's memory loss Use drug could influence cognition</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>